Management of Ertapenem-Induced Skin Rash

Initial Assessment and Drug Discontinuation

Stop ertapenem immediately if the rash is severe, progressive, or accompanied by systemic symptoms, as these may indicate serious cutaneous adverse reactions, according to Clinical Microbiology and Infection 1, 2
Document the timing, morphology, and distribution of the rash to characterize whether this represents an immediate-type or delayed-type reaction, as recommended by Clinical Microbiology and Infection 1, 2
Assess for signs of anaphylaxis or severe cutaneous adverse reactions, including Stevens-Johnson syndrome or toxic epidermal necrolysis, which require emergency management, as stated by Clinical Microbiology and Infection 1, 2

Apply topical corticosteroids, such as hydrocortisone 1% or moderate-potency agents like clobetasone butyrate 0.05%, to affected areas to reduce inflammation and erythema, as suggested by Praxis Medical Insights 3

Carbapenems share limited cross-reactivity with other beta-lactams; if the reaction was non-severe and delayed-type, other beta-lactams can generally be used safely, according to Clinical Microbiology and Infection 1, 2
For immediate-type reactions to ertapenem, cephalosporins can be administered in a monitored clinical setting with appropriate precautions, as recommended by Clinical Microbiology and Infection 1, 2
Consider non-beta-lactam alternatives, such as fluoroquinolones or aminoglycosides, depending on the infection type and susceptibility patterns, as suggested by the Journal of the American Academy of Dermatology 4, 5

Do not re-challenge with ertapenem if the initial reaction was severe, involved mucosal surfaces, or suggested a severe cutaneous adverse reaction, as warned by Clinical Microbiology and Infection 1, 2
Document this reaction clearly in the medical record and communicate it to other healthcare providers, pharmacies, and the patient to prevent inadvertent re-exposure, as advised by Clinical Microbiology and Infection 1, 2